During a protocol study for the efficacy of fluparoxan (a noradrenergic α2-antagonist) in depression, a positive effect on male erectile impotence has been observed in one case, with no important secondary effects. This result confirms the involvement of α2-antagonists in the handling of male impotence. The action on the erectile disorder appeared slightly before the antidepressive effect (2-3 weeks) and lasted for 6 weeks after the discontinuation of treatment, suggesting that the effects on impotence were not a mere reflection of the antidepressive action.
Brindley G.S. (1986) Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol87: 495-500
2.
Goldberg M.R., Robertson D. (1983) Yohimbine: a pharmacological probe for study of the alpha-2 adrenoceptor. Pharmacol Rev35: 143-180
3.
Krane R.J., Siroky M.B. (1981) Neurophysiology of erection. Urol Clin N Am8: 91-102
4.
Morales A., Surridge D H L, Marshall P.G., Fenemore J. (1982) Nonhormonal pharmacological treatment of organic impotence. J Urol128: 45-47
5.
Morley J.E. (1986) Impotence. Am J Med8: 897-905
6.
Pollack J.M., Gu J., Mina S., Bloom S.R. (1981) VIPergic nerves in the penis. Lancetii: 217-219
7.
Reid K., Morales A., Harris C., Surridge D H C, Condra M., Owen J. ( 1987) Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancetii: 421-423
8.
Riley A., Goodman R.E., Kellett J.M., Orr R. ( 1989) Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sex Marital Ther4: 17-26
9.
Susset J.G., Tessier C.D., Wincze J., Bansal S., Malhotra C., Schwacha M.G. (1988) Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol141: 1360-1363
10.
Willis E., Ottensen B., Wagner G., Sandler F., Fahrenkrug J. (1981) Vasoactive intestinal polypeptide (VIP) as a possible neuropeptide involved in penile erection. Acta Physiol Scand113: 545-547
